Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis ; volume:38 ; number:7 ; day:17 ; month:6 ; year:2021 ; pages:4100-4114 ; date:7.2021
Advances in therapy ; 38, Heft 7 (17.6.2021), 4100-4114, 7.2021
- Urheber
-
Olson, Amy L.
Patnaik, Padmaja
Hartmann, Nadine
Bohn, Rhonda L.
Garry, Elizabeth M.
Wallace, Laura
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01786-8
- URN
-
urn:nbn:de:101:1-2021101719342455281808
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Olson, Amy L.
- Patnaik, Padmaja
- Hartmann, Nadine
- Bohn, Rhonda L.
- Garry, Elizabeth M.
- Wallace, Laura
- SpringerLink (Online service)
Ähnliche Objekte (12)
Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis
Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype
The natural history of progressive fibrosing interstitial lung diseases
PKC-[zeta] deficiency in progressive experimental renal interstitial fibrosis
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Age related extracellular matrix and interstitial cell phenotype in pulmonary valves
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Progressive Massive Choroidal Neovascularization, an Aggressive Phenotype: Case Report
Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis
Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype
The natural history of progressive fibrosing interstitial lung diseases
PKC-[zeta] deficiency in progressive experimental renal interstitial fibrosis
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Age related extracellular matrix and interstitial cell phenotype in pulmonary valves
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Progressive Massive Choroidal Neovascularization, an Aggressive Phenotype: Case Report
Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis
Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype
The natural history of progressive fibrosing interstitial lung diseases
PKC-[zeta] deficiency in progressive experimental renal interstitial fibrosis
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Age related extracellular matrix and interstitial cell phenotype in pulmonary valves
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review